One option for macular degeneration cuts treatment costs from $2,000 to $50. April 4, 2011— -- One drug costs $50 per dose. The other costs $2,000 per dose. Now, new research shows that the drug ...

Onvansertib combined with FOLFIRI and Avastin shows dose-dependent improvements in tumor response and disease control for RAS ...

Regulators will clear a path for review of Genentech Inc.'s Avastin — one of the world's best-selling cancer drugs — as the company tries to extend the drug's use to certain types of cervical cancer.

WASHINGTON (AP) - Federal health authorities recommended Thursday that the drug Avastin no longer be used to treat breast cancer, saying recent studies failed to show the drug's original promise to ...

WASHINGTON, Dec 20 (Reuters) - Genentech Inc has resolved a dispute with doctors over the use of its cancer drug Avastin, a much less costly alternative to the biotech company's Lucentis for macular ...

Eye injections of the drug Avastin, used to treat retinal diseases, bring no greater risk of endophthalmitis, a potentially blinding eye infection, than injections with the much more expensive drug ...

BOSTON - In a widely expected move, the Food and Drug Administration said Thursday that it has begun the process of rescinding the market approval of Avastin for the treatment of advanced breast ...

WASHINGTON - The Food and Drug Administration and Genentech have warned doctors that Avastin, used to treat colorectal cancer, increases patients' risk of suffering heart ailments _ including chest ...

Health care firm Roche announced in a press release Thursday that the FDA has approved a new indication for its cancer drug Avastin. The new usage will allow Roche to market Avastin, in combination ...

Biocon Biologics has received the Food and Drug Administration’s green light for Jobevne (bevacizumab-nwgd), a biosimilar bevacizumab for intravenous use. Jobevne, which is a recombinant humanized ...